News
Get our top picks of the posters at AACR 2025 and learn more about the method behind them and the techniques used.
Native Hawaiian and other Pacific Islander people are 75% more likely to die from liver cancer and 2 to 3 times more likely ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral ...
Healthcare providers use many terms to describe the progress of a cancer or its response to treatment. The term "progressive disease" describes cancer that is growing, progressing, or worsening. There ...
NEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual Meeting
SAN DIEGO, April 29, 2025 /PRNewswire/ -- NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor ...
NEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual Meeting
SAB (PRNewsfoto/NEUVOGEN, Inc.) "These findings support that NGEN-143 can deliver an unprecedented breadth of targets and activate cytotoxic T cells, as compared to other currently available cancer ...
If you have bladder cancer, there are several treatment options. Your doctor will help you decide which one is best for you. Choosing the best treatment depends on a number of things ...
were presented in a poster presentation titled, "Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of Prostate Cancer." ...
non-small cell lung cancer and pancreatic cancer. The poster presented today describes Cogent’s internally-developed pan KRAS(ON) inhibitor program with selectivity over HRAS and NRAS and picomolar ...
Traditional Chinese medicine (TCM) is widely used in cancer care in China as an integral ... of TCM among Chinese immigrant patients. Such understanding fosters cultural competence and strengthens ...
non-small cell lung cancer and pancreatic cancer. The poster presented today describes Cogent’s internally-developed pan KRAS(ON) inhibitor program with selectivity over HRAS and NRAS and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results